* MEI Pharma Inc MEIP.OQ MEIP.O is expected to show a
fall in
quarterly revenue when it reports results on February 8
(estimated).
* The San Diego California-based company is expected to
report a
66.6% decrease in revenue to $6.078 million from $18.22 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for MEI Pharma Inc is
for a
loss of 15 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for MEI Pharma
Inc is
$3, above its last closing price of $0.33.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.14 -0.14 -0.12 Beat 16.3
Jun. 30 2022 -0.18 -0.19 -0.12 Beat 35.4
Mar. 31 2022 -0.18 -0.18 -0.07 Beat 61.6
Dec. 31 2021 -0.20 -0.20 -0.05 Beat 75.3
Sep. -0.12 -0.13 -0.11 Beat 12.7
30 2021
Jun. 30 2021 -0.18 -0.17 -0.05 Beat 71.4
Mar. 31 2021 -0.17 -0.16 -0.28 Missed -72.3
Dec. 31 2020 -0.14 -0.13 -0.10 Beat 24.7
This summary was machine generated February 6 at 11:01 GMT. All
figures in US dollars unless otherwise stated